<DOC>
	<DOCNO>NCT00779922</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetic profile Revlimid® patient present Multiple Myeloma impair renal function , safety Revlimid® enrol patient population . evaluate efficacy Revlimid®-Dexamethasone combination patient present MM impair renal function completion 3 cycle treatment .</brief_summary>
	<brief_title>Pharmacokinetics Lenalidomide ( Revlimid® ) Patients With Multiple Myeloma Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Documented diagnosis relapse refractory multiple myeloma ( MM ) . Age &gt; 18 year time signing informed consent form Stable renal function Documented amyloidosis Any prior use Revlimid ® Any contraindication Revlimid ® especially : Lack acceptable method birth control female childbearing potential ( FCPB ) Men n't agree use condom study 4 week last study drug intake partner FCPB . Pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>impaired renal function</keyword>
</DOC>